Rat study finds CB2 agonist reduced extract-related liver damage

Protective effect of cannabinoid type 2 receptor agonist (JWH-133) against hepatotoxicity induced by Prangos ferulacea Lindl. extract.

Experimental physiology • • Highly Relevant
🤖

AI Summary

This animal study asked whether activating the cannabinoid type 2 receptor (CB2) with JWH-133 could reduce liver injury caused by Prangos ferulacea extract, and whether that injury involved endoplasmic reticulum stress or inflammation. 37 rats were assigned to a control group, PF extract alone, PF extract plus JWH-133, or JWH-133 alone. Researchers assessed liver tissue, cell death, stress and inflammatory markers, liver enzymes, and blood proteins.

PF extract produced significantly more histopathological liver damage than the control, JWH-133-only, and combined-treatment groups. Caspase-3 staining, a marker associated with apoptosis, was intense with PF extract alone but limited when JWH-133 was added, supporting an apparent protective effect in liver tissue. However, the measured ER-stress markers and inflammatory cytokines did not differ significantly between groups, while calpain levels were higher in the PF-exposed groups. The abstract therefore supports an ER-stress-independent mechanism as a possibility, not a proven explanation. This is an abstract-based summary of a small rat study; it cannot establish that JWH-133 or CB2 activation is safe or effective for liver disease in humans, and the reported findings should not be interpreted as a treatment recommendation.

💡 Key Findings

1
Prangos ferulacea extract caused significantly greater liver tissue damage in rats than the control and comparator groups.
Limited
35%
2
Adding the CB2 agonist JWH-133 was associated with less histopathological damage and more limited caspase-3 immunoreactivity than PF extract alone.
Limited
35%
3
The tested endoplasmic reticulum stress markers and IL-17/IL-23 inflammatory measures showed no significant between-group differences.
Limited
35%
4
Calpain levels differed significantly among groups and were higher in both PF-exposed groups than in controls, suggesting a possible pathway requiring further study.
Limited
30%

📄 Original Abstract

This study investigated Prangos ferulacea (PF)-induced hepatotoxicity, its potential association with endoplasmic reticulum (ER) stress and proinflammatory cytokines, and the effect of the cannabinoid type 2 receptor agonist JWH-133. Rats (n&#xa0;=&#xa0;37) were divided into four groups: control-sham group (CSG, n&#xa0;=&#xa0;9), PF extract group (PG, n&#xa0;=&#xa0;9), PF extract + JWH-133 group (PJG, n&#xa0;=&#xa0;9) and JWH-133 group (JG, n&#xa0;=&#xa0;10). Hepatic ER stress markers (CHOP, GRP78 and ATF4), interleukin (IL)-17, IL-23, heat shock protein 72 (HSP72), and calpain, as well as serum IL-17, IL-23, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein and albumin, were assessed. Liver histology was evaluated using haematoxylin-eosin staining, and apoptosis was assessed by caspase-3 immunohistochemistry. No significant between-group differences were observed in hepatic GRP78, CHOP, ATF4, IL-17 or IL-23 levels. Similarly, serum IL-17 and IL-23 levels did not differ significantly among the groups. Calpain levels differed significantly among the groups (P =&#xa0;0.0017), with higher levels in PG (P =&#xa0;0.0325) and PJG (P =&#xa0;0.0076) than in CSG. Compared with CSG, PG and PJG showed lower ALT (P =&#xa0;0.0021 for both), AST (P =&#xa0;0.0021 for both), albumin (P =&#xa0;0.0031 and P =&#xa0;0.0016, respectively) and total protein (P =&#xa0;0.0056 and P =&#xa0;0.0017, respectively) levels. Histopathological damage was significantly greater in PG than in CSG, PJG and JG (all P <&#xa0;0.0001). Caspase-3 immunoreactivity was intense in PG and limited in PJG. PF extract caused marked liver injury without clear canonical ER stress activation. JWH-133 attenuated histopathological damage, consistent with the potential role of CB2 receptor activation. These findings support ER stress-independent mechanisms and warrant further investigation of CB2 activation as a hepatoprotective strategy.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.